Dilpacimab

DB16140Investigational

Dilpacimab is under investigation in clinical trial NCT03368859 (A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and...

Mechanism: Pharmacologically active on Vascular endothelial growth factor A, long form and Delta-like protein 4
Curator reviewed
Also known as: Immunoglobulin, anti-(notch ligand dll4/vascular endothelial growth factor) (synthetic human pr-1283233 heavy chain), disulfide with synthetic human pr-1283233 light chain, dimer
Code names: ABT-165 · PR-1283233

Resolves to

Compound

UNIIF27LAH6D5OCAS1791420-09-1

Targets

P15692VEGFAQ9NR61DLL4

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dilpacimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account